Lupin today announced the launch of Rufinamide Tablets USP, 200 mg and 400 mg, to market a generic equivalent of Banzel® Tablets, 200 mg and 400 mg, of Eisai Inc.

Rufinamide Tablets (RLD Banzel®) had estimated annual sales of USD 138 million in the U.S. (IQVIA MAT October 2022).

Powered by Capital Market - Live News

The drug major announced that it launched Rufinamide tablets USP, 200 mg and 400 mg in the United States.

Rufinamide is used with other medications to prevent or control seizures (epilepsy) associated with Lennox-Gastaut syndrome (LGS).

Rufinamide tablets (RLD Banzel) had estimated annual sales of $138 million in the U.S. (IQVIA MAT October 2022).

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

On consolidated basis the company reported net profit of Rs 129.73 crore in Q2 FY23 as against net loss of Rs 2098.04 crore in Q2 FY22. Revenue from operations rose 2.2% to Rs 4091.16 crore in Q2 FY23 as compared to Rs 4003.42 crore in Q2 FY22.

Shares of Lupin shed 1.05% at Rs 767.20 on the BSE.

Powered by Capital Market - Live News

Lupin Ltd gained for a fifth straight session today. The stock is quoting at Rs 757.5, up 0.81% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.19% on the day, quoting at 18652.7. The Sensex is at 62756.06, up 0.12%. Lupin Ltd has risen around 8.37% in last one month.

Meanwhile, Nifty Metal index of which Lupin Ltd is a constituent, has risen around 0.89% in last one month and is currently quoting at 13087.35, up 0.06% on the day. The volume in the stock stood at 5.57 lakh shares today, compared to the daily average of 17.18 lakh shares in last one month.

The benchmark December futures contract for the stock is quoting at Rs 765.85, up 1.06% on the day. Lupin Ltd is down 13.07% in last one year as compared to a 8.66% spurt in NIFTY and a 2.58% spurt in the Nifty Metal index.

The PE of the stock is 44.91 based on TTM earnings ending September 22.

Powered by Capital Market - Live News

Formoterol Fumarate is used to control chronic obstructive pulmonary disease (COPD) that includes chronic bronchitis and emphysema.

Formoterol Fumarate Inhalation Solution, 20 mcg/2 mL per Unit-Dose Vial is a generic equivalent of Perforomist Inhalation Solution, 20 mcg/2 mL, of Mylan Specialty, L.P.

Formoterol Fumarate Inhalation Solution (RLD Perforomist) had estimated annual sales of $268 million in the U.S. (IQVIA MAT September 2022).

Separately, Lupin's wholly-owned subsidiary in Brazil, MedQuímica Indústria Farmacêutica (MedQuímica), has signed a definitive agreement to acquire all rights to nine medicines from BL Indústria Ótica, a subsidiary of Bausch Health Companies Inc.

The nine products includes Limbitrol, Melleril and Dalmadorm for Central Nervous System related conditions, Bacrocin, Glyquin, Solaquin, Oxipelle and Efurix as topical oncological treatments, and Cuprimine for the treatment of Wilson's disease.

Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

On consolidated basis the company reported net profit of Rs 129.73 crore in Q2 FY23 as against net loss of Rs 2098.04 crore in Q2 FY22. Revenue from operations rose 2.2% to Rs 4091.16 crore in Q2 FY23 as compared to Rs 4003.42 crore in Q2 FY22.

Powered by Capital Market - Live News